IDUA (Iduronidase), also known as alpha-L-iduronidase, is a lysosomal hydrolase that catalyzes the hydrolysis of alpha-L-iduronic acid residues from the non-reducing ends of glycosaminoglycans (GAGs) heparan sulfate and dermatan sulfate. This enzyme is essential for the complete lysosomal degradation of GAGs, and its deficiency causes mucopolysaccharidosis type I (MPS I), a severe lysosomal storage disorder characterized by progressive multisystem disease including neurodegeneration. The IDUA gene encodes a protein of 653 amino acids that is targeted to the lysosome via mannose-6-phosphate modification, and proper enzyme trafficking is essential for its function [1][2][3][4].
| IDUA — Alpha-L-Iduronidase |
|---|
| Gene Symbol | IDUA |
| Full Name | Alpha-L-iduronidase |
| Chromosomal Location | 4p16.3 |
| NCBI Gene ID | 3419 |
| OMIM | 609014 |
| Ensembl ID | ENSG00000127418 |
| UniProt ID | P35475 |
| Associated Diseases | [Mucopolysaccharidosis Type I](/diseases/mucopolysaccharidosis-type-1) (Hurler Syndrome), [Scheie Syndrome](/diseases/mucopolysaccharidosis-type-1) |
¶ Protein Structure and Function
Alpha-L-iduronidase is a 653-amino acid glycoprotein with a molecular weight of approximately 76 kDa. The enzyme undergoes several post-translational modifications:
- Signal peptide: N-terminal targeting to the secretory pathway
- Propeptide: Cleaved in the ER to generate mature enzyme
- N-glycosylation: Multiple sites for mannose-6-phosphate addition
- Compartmental targeting: Mannose-6-phosphate directs lysosomal localization
The enzyme catalyzes the hydrolysis of alpha-L-iduronic acid residues from GAGs through:
- Acid-base catalysis: Residues in the active site facilitate hydrolysis
- Substrate specificity: Recognizes the non-reducing end of heparan sulfate and dermatan sulfate
- Processivity: Acts repeatedly along the GAG chain
¶ Glycosylation and Trafficking
Proper trafficking requires:
- N-linked glycosylation in the ER
- Mannose-6-phosphate modification in the Golgi
- Recognition by mannose-6-phosphate receptors
- Delivery to lysosomes
Alpha-L-iduronidase works in concert with other lysosomal sulfatases to degrade GAGs:
- Heparan sulfate degradation: IDUA removes iduronic acid residues
- Dermatan sulfate degradation: Generates substrates for other enzymes
- Coordinated action: Works with sulfamidase (SGSH), N-acetylgalactosamine-4-sulfatase (ARSB), and others
The complete degradation pathway:
- Endocytosis of GAGs: Brought into lysosomes via autophagy
- Sequential hydrolysis: Multiple enzymes act in concert
- Export of degradation products: Transported to the cytosol for reuse
MPS I, caused by IDUA deficiency, is a spectrum disorder:
- Onset: First year of life
- Progression: Rapid neurodegenerative decline
- Phenotype: Coarse facial features, organomegaly, skeletal abnormalities (dysostosis multiplex)
- Neurological: Hydrocephalus, spinal cord compression, developmental regression
- Survival: Without treatment, Usually fatal in first decade
- Onset: Childhood to adulthood
- Progression: Slower, variable
- Phenotype: Joint stiffness, corneal clouding, carpal tunnel
- Intelligence: Often normal
- Onset: 2-4 years
- Progression: Intermediate
- Survival: Into adolescence or early adulthood
In MPS I, brain imaging reveals [12]:
- White matter abnormalities: Periventricular hyperintensities
- Hydrocephalus: Communicating hydrocephalus common
- Cervical compression: Foramen magnum stenosis
- Carotid artery disease: Vessel wall thickening
Neurocognitive decline in MPS I involves [13]:
- Developmental regression
- Impaired processing speed
- Executive dysfunction
- Language regression
Recombinant human alpha-L-iduronidase (laronidase, Aldurazyme):
- Delivery: Weekly intravenous infusions
- Effects: Reduces substrate storage, improves endurance
- Limitations: Does not cross the blood-brain barrier
- CNS effects: Minimal (BBB limits CNS benefit)
ERT has limited efficacy for neuropathic MPS I due to failure to cross the blood-brain barrier [14]. Research into BBB-penetrant enzyme formulations is ongoing.
HSCT provides:
- Enzyme source: Donor-derived cells produce enzyme
- Microglial replacement: CNS engrafts with donor microglia
- Stabilization: Can halt neurological progression
- Risks: Graft-versus-host disease, mortality
HSCT remains the standard of care for severe MPS I with neurological involvement [7]. Early transplantation before significant neurocognitive decline is critical.
AAV-mediated IDUA delivery has shown promise in animal models [8][9]:
- Vectors: AAV9, AAVrh.10 (CNS targeting)
- Delivery: Intravenous or intrathecal administration
- Efficacy: Reverses storage in models
- Clinical trials: In development
Approaches to reduce GAG substrate accumulation [10]:
- Small molecule inhibitors: Reduce GAG synthesis
- Combination with ERT: May enhance efficacy
- Limitations: Not clinically approved for MPS I
Early detection enables [11]:
- Early treatment initiation
- Pre-symptomatic therapy
- Optimized outcomes
- Family counseling
Alpha-L-iduronidase is expressed in most tissues:
- Highest: Liver, spleen, kidney
- Moderate: Brain, lung, heart
- Cellular: Especially in macrophages and microglia
Within the brain:
- Neurons: Variable expression
- Astrocytes: Baseline expression
- Microglia: High expression (important for therapy)
- Choroid plexus: Contributes to CSF enzyme
The storage material in MPS I consists of:
- Heparan sulfate: Primary storage in neurons
- Dermatan sulfate: Storage throughout body
- Partial degradation products: Accumulate as storage
- Lysosomal enlargement: Swollen lysosomes
- Cytoplasmic vacuolization: Observed in many cell types
- Neuronal storage: Leads to neurodegeneration
- Inflammation: Secondary inflammatory responses
The BBB presents a therapeutic challenge:
- Standard ERT does not cross BBB
-HSCT provides CNS enzyme via microglia
- Gene therapy vectors are being engineered for BBB penetration
Idua knockout mice display:
- Storage accumulation
- shortened lifespan
- Behavior abnormalities with age
MPS I in dogs shows:
- More severe phenotype
- Good model for therapy studies
Swine and non-human primate models are used for translational studies.
¶ Mermaid Diagram: IDUA Function and Therapy
flowchart TD
A["Glycosaminoglycans<br/>HS, DS"] --> B["IdUA<br/>Enzyme"]
B --> C["Iduronic Acid<br/>Removal"]
C --> D["Further<br/>Degradation"]
D --> E["Monosaccharides<br/>Export"]
F["IDUA<br/>Deficiency"] --> G["Heparan Sulfate<br/>Storage"]
F --> H["Dermatan Sulfate<br/>Storage"]
G --> I["Lysosomal<br/>Enlargement"]
H --> I
I --> J["Cellular<br/>Dysfunction"]
J --> K["Neurodegeneration"]
L["ERT"] --> M["Systemic<br/>Clearance"]
L --> N["Limited CNS<br/>Effect"]
O["HSCT"] --> P["Microglial<br/>Engraftment"]
P --> Q["CNS Enzyme<br/>Production"]
R["Gene Therapy"] --> S["BBB-Penetrant<br/>Delivery"]
S --> T["Global<br/>Correction"]
IDUA mutations show variety:
- Missense mutations: Most common
- Nonsense mutations: Severe phenotype
- Splice site mutations: Variable
Certain mutations correlate with [12]:
- Severe phenotype: Q70X, W402X
- Attenuated: A327T, P533R